Abstract
Objectives
Little epidemiologic research has examined the practice of electroconvulsive therapy (ECT). We investigated socio-demographic and clinical characteristics, service use, and psychotropic medication prescription patterns associated with ECT use at a Veterans Health Administration Medical Center.
Methods
Among veterans receiving specialty mental health services, we compared those who received ECT with those who did not using bivariate chi-square and t-tests and multivariate logistic regression.
Results
In fiscal year 2012, 11,117 veterans received specialty mental health services, of whom 50 received ECT (0.45%) in FY2012 or FY2013. Those who received ECT were more likely to be diagnosed with Major Depressive or Bipolar Disorders and had substantially higher levels of mental health service utilization (Cohen’s d>0.75) and psychotropic prescription fills, including antidepressants (Cohen’s d=2.66), antipsychotics (Cohen’s d=2.15), lithium (Cohen’s d=1.34), mood stabilizers (Cohen’s d=1.30), and anxiolytic/sedative/hypnotics (Cohen’s d=1.34).
Conclusions
Our findings suggest that ECT is used as a treatment of last resort, although available evidence and guidelines recommend wider use.
Introduction
Electroconvulsive therapy (ECT) is among the most effective treatments for Major Depressive Disorder (MDD), with response rates of 80–90% when used as first-line treatment and response rates of 50–60% in Treatment-Resistant Depression (TRD) 1. Despite its efficacy, ECT is thought to be under-utilized because of stigma, restricted access due to limited availability, high procedure costs, the risk of cognitive side effects, and legal restrictions in some locales. In countries where its use has been assessed longitudinally, ECT use has declined 2, 3. One potential additional reason for this decline may be related to the reduction in the number of centers that offer ECT on an inpatient basis 3. However, since recent technical advances (e.g., ultra-brief pulse width, right unilateral placement) have substantially reduced cognitive risks associated with ECT (most notably, autobiographical memory 4) and it can increasingly be offered on an outpatient basis, the limited and declining use of ECT may be denying optimal treatment to many patients.
While Major Depressive Disorder is the most common indication and the indication for which the most evidence exists 5, ECT has also been shown to be effective for other disorders including bipolar depression 6, catatonia 5, mania 7, and positive symptoms of schizophrenia 8. More limited evidence has shown benefit in treatment-resistant cases of OCD 9.
In view of evidence of its effectiveness and suggestions that ECT is underused 10, there is a need for clinical epidemiological service utilization studies of the community practice of ECT in the United States. Recent reports in international settings 11–15 show a wide variation in the prevalence of ECT use, with recent treated prevalence estimates ranging from 41 ECT patients/100,000 population in Sweden 11 to 1.1 ECT patients/100,000 population in Poland 2. A recent systematic review and meta-analysis on the use of ECT internationally only included US studies dating from 1999 or earlier as no more recent studies were available 2. The most recent picture of the US practice of ECT comes from Case et al., whose analysis from the National Inpatient Survey showed a decline in inpatient use of ECT from 1993 to 2009, which the authors attribute to a reduction in the number of hospitals that offer this service 3. However, their analysis was limited by the fact that it only examined ECT delivery on an inpatient basis and did not compare ECT recipients and other mental health patients. With significant changes in criteria for and lengths of stay of psychiatric hospitalization over the time period analyzed, many centers increasingly provide ECT on an outpatient basis for a large portion of ECT patients. Pfeiffer et al., characterized demographic characteristics within the Veterans Health Administration between those diagnosed with depression who received ECT treatment and those who did not 10. However, they did not examine patterns of service use or psychotropic medication fills.
To better characterize community practice of ECT, we used cross-sectional data on ECT use among veterans receiving specialty psychiatric care at a large Veterans Affairs Medical Center in New England to identify overall rates of use and to compare veterans who received ECT and those who did not on sociodemographic characteristics; psychiatric and medical co-morbid diagnoses; use of medical and mental health services and psychotropic medication fills.
Methods
Sample
Data were drawn from administrative records of all veterans who received specialty mental health care in Fiscal year (FY) 2012 (October 1, 2011 to September 30, 2012) at the VA Connecticut Healthcare System (VACT). Records identified all veterans who received ECT services from VACT in either the index year (FY 2012) or FY 2013. The study was approved the VA Connecticut institutional review board and was granted a waiver of informed consent.
Measures
Database measures included sociodemographic characteristics, service utilization data, medical and psychiatric diagnoses, and psychotropic medication prescription history during FY2012. Sociodemographic characteristics included age, gender, race, service connected disability status, pension status, and whether the patient had been homeless during the year. Homelessness was also assessed using codes representing use of specialized services for homeless veterans or having a V60 (homelessness) ICD-9 Code. Medical and psychiatric diagnoses were based on ICD-9 codes in VA administrative files. Overall medical comorbidity was measured by the Charlson Comorbidity Index 16.
Service utilization was measured by the total number of medical/surgical visits per patient, the total number of emergency room visits, and total number of psychiatric or substance use treatment visits during the index year. Because ECT is often performed on an inpatient basis, hospitalization could not be used as a distinguishing criterion.
Psychotropic medication prescription fills during the year were categorized into six groups: antipsychotics, antidepressants, anxiolytics/sedative/hypnotics, stimulants, mood stabilizers, and lithium. Measures includes the total number of prescriptions filled in the current year in each category and in all combined categories during the current year.
Analysis
Analysis proceeded in two steps. First bivariate analyses using chi square and t-tests compared the significance of differences between veterans who received ECT and those who did not on socio-demographic characteristics, medical and psychiatric diagnoses, service utilization, and psychotropic medication fills. In comparing continuous variables, we utilized Welch’s t-test (also known as Satterthwaite test) when F-tests indicated unequal variances. Further details of Welch’s t-test can be found elsewhere 17. We also present effect sizes reflecting the magnitude of differences using Cohen’s d (difference in mean divided by pooled standard deviation) for continuous variables and risk ratios for categorical variables. Continuous variables with a Cohen’s d > 0.5 and categorical variables with risk ratios >2.0 or <0.5 were considered to reflect a substantial difference between veterans who received ECT and those who did not.
Next, logistic regression was used to identify characteristics that independently differentiated veterans who received ECT and those who did not. Measures that substantially differentiated groups on bivariate analysis were entered into a step-wise logistic regression model. A measure of the date of first contact with VHA during the year was used for differences in days of exposure to VHA treatments.
Results
Sociodemographic Characteristics
In FY2012, 11,117 veterans received specialty mental health services at VACT and 50 (0.45%) subsequently received ECT in FY2012 or FY2013. The sample was overwhelmingly male (93%) and Caucasian (83%), with a mean (SD) age of 56.5 (16.4) (Table 1). Almost half (46%) had a service-connected disability and 14% had been homeless during the year. African Americans were less likely to receive ECT than others and recipients of VA pensions were significantly more likely to receive ECT.
Table 1.
No ECT group N=11067 |
ECT group N=50 |
Effect size
|
Test statistic
|
df | p value | |||||
---|---|---|---|---|---|---|---|---|---|---|
Mean/N | SD/% | Mean/N | SD/% | Risk Ratio / | Cohen’s d | Chi square / | t statistic | |||
Demographic Variables | ||||||||||
| ||||||||||
Male | 10255 | 0.9 | 45 | 0.9 | 0.97 | 0.04 | 1 | 0.84 | ||
| ||||||||||
Age (years)† | 56.5 | 16.4 | 59.6 | 10.5 | 0.19 | −2.12 | 50 | 0.04 | ||
| ||||||||||
Race* | ||||||||||
| ||||||||||
White | 8488 | 0.8 | 44 | 0.9 | 1.08 | 1.32 | 1 | 0.25 | ||
| ||||||||||
African American | 1440 | 0.1 | 2 | 0.0 | 0.29 | 3.70 | 1 | 0.05 | ||
| ||||||||||
Other race | 57 | 0.0 | 2 | 0.0 | 7.32 | 11.69 | 1 | <0.01 | ||
| ||||||||||
Disability Measures | ||||||||||
| ||||||||||
Service Connected 50% or more | 3231 | 0.3 | 17 | 0.3 | 1.17 | 0.42 | 1 | 0.52 | ||
| ||||||||||
Service Connected less than 50% | 1886 | 0.2 | 6 | 0.1 | 0.70 | 0.77 | 1 | 0.38 | ||
| ||||||||||
Receives VA Pension | 383 | 0.0 | 5 | 0.1 | 2.89 | 6.33 | 1 | 0.01 | ||
| ||||||||||
Homeless during the year | 1558 | 0.1 | 7 | 0.1 | 0.99 | 0.06 | 1 | 0.80 | ||
| ||||||||||
Medical Comorbidities | ||||||||||
| ||||||||||
Congestive Heart Failure | 5403 | 0.5 | 27 | 0.5 | 1.11 | 0.70 | 1 | 0.40 | ||
| ||||||||||
Cerebrovascular Accident | 527 | 0.0 | 3 | 0.1 | 1.26 | 0.19 | 1 | 0.66 | ||
| ||||||||||
Chronic Obstructive Airway Disease | 1739 | 0.2 | 8 | 0.2 | 1.02 | 0.01 | 1 | 0.92 | ||
| ||||||||||
Diabetes Mellitus | 2366 | 0.2 | 12 | 0.2 | 1.12 | 0.27 | 1 | 0.60 | ||
| ||||||||||
Cancer | 1047 | 0.1 | 4 | 0.1 | 0.85 | 0.09 | 1 | 0.76 | ||
| ||||||||||
Any Pain Diagnosis | 5596 | 0.5 | 28 | 0.6 | 1.11 | 0.32 | 1 | 0.57 | ||
| ||||||||||
Charlson Medical Severity Diagnosis Index | 1.6 | 2.0 | 1.9 | 2.2 | 0.16 | −1.11 | 11,115 | 0.27 | ||
| ||||||||||
Psychiatric Diagnosis | ||||||||||
| ||||||||||
Schizophrenia | 982 | 0.1 | 11 | 0.2 | 2.48 | 9.72 | 1 | <0.01 | ||
| ||||||||||
Bipolar disorder | 1076 | 0.1 | 17 | 0.3 | 3.50 | 31.18 | 1 | <0.01 | ||
| ||||||||||
Major depression | 3024 | 0.3 | 40 | 0.8 | 2.93 | 60.66 | 1 | <0.01 | ||
| ||||||||||
Other depression (e.g. dysthymia) | 3893 | 0.4 | 29 | 0.6 | 1.65 | 8.28 | 1 | <0.01 | ||
| ||||||||||
Post-traumatic stress disorder | 4289 | 0.4 | 16 | 0.3 | 0.83 | 1.41 | 1 | 0.24 | ||
| ||||||||||
Anxiety disorder | 2664 | 0.2 | 16 | 0.3 | 1.33 | 1.33 | 1 | 0.25 | ||
| ||||||||||
Adjustment disorder | 1224 | 0.1 | 3 | 0.1 | 0.54 | 1.47 | 1 | 0.23 | ||
| ||||||||||
Personality disorder | 356 | 0.0 | 8 | 0.2 | 4.97 | 24.36 | 1 | <.01 | ||
| ||||||||||
Any drug | 1894 | 0.2 | 17 | 0.3 | 1.99 | 7.10 | 1 | 0.01 | ||
| ||||||||||
Any substance abuse diagnosis | 3071 | 0.3 | 28 | 0.6 | 2.02 | 16.06 | 1 | <.01 | ||
| ||||||||||
Alcohol dependence | 2379 | 0.2 | 21 | 0.4 | 1.95 | 11.55 | 1 | <0.01 | ||
| ||||||||||
Drug dependence | 1894 | 0.2 | 17 | 0.3 | 1.99 | 7.10 | 1 | 0.01 | ||
| ||||||||||
Service Use | ||||||||||
| ||||||||||
Any Mental Health Inpatient Treatment | 648 | 0.1 | 27 | 0.5 | 9.22 | 178.47 | 1 | <0.01 | ||
| ||||||||||
Emergency Room Visits† | 0.8 | 2.3 | 2.8 | 3.3 | 0.87 | −4.23 | 49 | <0.01 | ||
| ||||||||||
Medical Surgical Visits | 12.4 | 15.8 | 15.7 | 13.8 | 0.21 | −1.48 | 11,115 | 0.14 | ||
| ||||||||||
Psychiatric or Substance Abuse Outpatient Visits† | 15.9 | 32.7 | 42.0 | 58.4 | 0.80 | −3.17 | 49 | <0.01 | ||
| ||||||||||
Psychotropic Medication Prescriptions | ||||||||||
| ||||||||||
Antidepressant Prescriptions† | 5.9 | 9.3 | 31.3 | 31.4 | 2.66 | −5.71 | 49 | <0.01 | ||
| ||||||||||
Antipsychotic Prescriptions† | 2.6 | 7.9 | 20.2 | 33.0 | 2.15 | −3.78 | 49 | <0.01 | ||
| ||||||||||
Anxiolytic/Sedative/Hypnotic Prescriptions† | 2.8 | 5.9 | 10.8 | 15.0 | 1.34 | −3.79 | 49 | <0.01 | ||
| ||||||||||
Stimulant Prescriptions† | 0.2 | 1.5 | 0 | 0.0 | −0.12 | 12.57 | 11,066 | <0.01 | ||
| ||||||||||
Lithium† | 0.2 | 1.8 | 2.8 | 7.8 | 1.34 | −2.31 | 49 | 0.02 | ||
| ||||||||||
Anticonvulsant/mood stabilizer† | 1.7 | 5.6 | 9.1 | 15.7 | 1.30 | −3.33 | 49 | <0.01 | ||
| ||||||||||
All Psychotropics*† | 14.4 | 20.1 | 74.2 | 80.1 | 2.87 | −5.28 | 49 | <0.01 | ||
|
df - degrees of freedom;
Missing data (≤7.6%) from these variables;
Welch’s t test assuming unequal variance
Clinical Diagnoses
Both groups had substantial medical comorbidities but there were no significant or substantial differences in the prevalence of any particular medical illnesses or on the overall Charlson Comorbidity Index (Cohen’s d=0.15). Compared to those who did not receive ECT, the ECT group had significantly and substantially higher rates of most psychiatric diagnoses, including schizophrenia (Risk Ratio [RR] =2.5), bipolar disorder (RR=3.5), major depressive disorder (RR=2.9), other depressive disorders (e.g., dysthymia, RR=1.6), personality disorder (RR=4.9), and alcohol or drug dependence considered together (RR=2.0).
Service Utilization
Veterans who received ECT had significantly and substantially higher levels of service use compared to those who did not receive ECT on measures of average emergency room visits per patient, and psychiatric or substance abuse outpatient visits, all with large effect sizes (all Cohen’s d>0.75). There was no significant difference in outpatient medical/surgical visits between groups (Table 1).
Psychotropic Prescription Patterns
Total psychotropic medication prescription fills per patient during FY 2012 were significantly and much higher among the ECT group compared to the no-ECT group (mean 74.2 v. 14.4, t=−5.25, p<0.0001), with a very large effect size (Cohen’s d=2.87). More specifically, the ECT group had substantially higher numbers of prescriptions for all individual classes of psychotropic medications examined except for stimulants, with very large effect sizes for antidepressants and antipsychotics (Cohen’s d > 2.0), as well as for anxiolytic/sedative/hyponotics, lithium, and anticonvulsant/mood stabilizers (Cohen’s d > 1.3).
Logistic Regression Model
Stepwise logistic regression showed only three variables were independently associated with treatment with ECT: major depressive disorder (Odds ratio=8.47, 95% confidence interval (CI) 4.1–17.5), bipolar disorder (Odds ratio=3.00, 95% CI= 1.6–5.8), and the number of psychotropic prescription fills (Odds ratio per 10 prescriptions/year=1.25, 95% CI= 1.19–1.30). With a c-statistic of 0.87, this model had a very good fit with only these three variables.
The stepwise logistic regression analysis was repeated on the subgroup of patients diagnosed with MDD and the only two variables that were significant were a diagnosis of bipolar disorder (p<.002) and the number of filled prescriptions (p<0.0001), again with a high c statistic of 0.83.
Discussion
In this study of veterans receiving specialty mental health care at a large VA medical center, less than 1% of patients receiving specialty mental health care received ECT and there were substantial differences in psychiatric diagnoses, mental health service utilization, and psychotropic prescription fill patterns between those who received ECT and those who did not. In a stepwise logistic regression model, the differences between veterans who underwent ECT and those who did not were explained entirely by a diagnosis of major depressive disorder or bipolar disorder and the total number of psychotropic prescriptions per year.
Unsurprisingly, veterans who received ECT were significantly more likely to carry diagnoses of major depressive disorder and bipolar disorder. However, it was somewhat unexpected that those receiving ECT were also more likely to be diagnosed with personality disorder, alcohol or drug dependence on the bivariate analysis. High rates of alcohol and drug dependence have generally not been reported in previous literature characterizing ECT patients among veterans 10 indicating that in this context current substance use disorders were not an exclusion criterion for ECT.
Our data suggest that approximately 1 patient in 221who receive specialty mental health care receive ECT. It is difficult to contextualize this within prior research that bases prevalence estimates on the general population. However, our finding that ECT patients receive much higher numbers of mental health outpatient visits and, especially, more psychotropic prescriptions, especially antidepressants, than other veterans suggests that this treatment is used as an option of last resort for patients receiving exceptionally intensive treatment, a practice which the APA Task Force recommend against 5. Further, as suggested by the high comorbidities of personality disorder and substance use disorder in this dataset, in some cases ECT may have been used as a treatment of last resort in patients who are otherwise very difficult to treat, perhaps when the treating clinician did not know what else might possibly be useful.
Several limitations require comment. Most notably, our analysis is limited to a single medical center and thus reflect the practice patterns of a small number of ECT practitioners. Further, our sample comprises a relatively older, predominantly white group of veterans who reside in the New England area; hence, the generalizability of our findings to non-veterans populations or other regions is unknown. Finally, our data is drawn from administrative databases, which can have significant limitations (such as diagnosis being made from ongoing clinical interview and not structured research interviews) and do not include important clinical measures such as number of failed antidepressant trials, length of current depressed episode, psychotic versus non-psychotic depression, or clinical response to ECT.
Despite these limitations, use of ECT is exceptionally rare and stark differences were found between patients receiving ECT and those who did not. Our findings suggest that, contrary to professional guidelines, ECT is used as a treatment of last resort and may therefore be under-utilized. Larger, more representative samples of longitudinal epidemiological studies should be conducted to better characterize ECT patterns in the United States.
Acknowledgments
The authors acknowledge support from the National Institutes of Health (T32MH062994-15, 5R25MH071584-09), the Thomas Detre Fellowship, the Brain & Behavior Research Foundation, and the Robert E. Leet and Clara Guthrie Patterson Trust Foundation. Elina Stefanovics PhD conducted the statistical analyses. The authors acknowledge Mayra Ortiz for her generous assistance in preparing the table.
Footnotes
Conflicts of interest: None.
Disclosures: None.
References
- 1.Greenberg RM, Kellner CH. Electroconvulsive therapy: a selected review. Am J Geriatr Psychiatry. 2005 Apr;13(4):268–281. doi: 10.1176/appi.ajgp.13.4.268. [DOI] [PubMed] [Google Scholar]
- 2.Lesage A, Lemasson M, Medina K, et al. The Prevalence of Electroconvulsive Therapy Use Since 1973: A Meta-analysis. J ECT. 2016 May 25; doi: 10.1097/YCT.0000000000000320. [DOI] [PubMed]
- 3.Case BG, Bertollo DN, Laska EM, et al. Declining use of electroconvulsive therapy in United States general hospitals. Biol Psychiatry. 2013 Jan 15;73(2):119–126. doi: 10.1016/j.biopsych.2012.09.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Sackeim HA, Prudic J, Nobler MS, et al. Effects of pulse width and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. Brain Stimul. 2008 Apr;1(2):71–83. doi: 10.1016/j.brs.2008.03.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Weiner RD, Coffey CE, Fochtmann LJ, et al. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. 2. American Psychiatric Association; 2001. [Google Scholar]
- 6.Schoeyen HK, Kessler U, Andreassen OA, et al. Treatment-resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment. Am J Psychiatry. 2015 Jan;172(1):41–51. doi: 10.1176/appi.ajp.2014.13111517. [DOI] [PubMed] [Google Scholar]
- 7.Small JG, Klapper MH, Kellams JJ, et al. Electroconvulsive treatment compared with lithium in the management of manic states. Arch Gen Psychiatry. 1988 Aug;45(8):727–732. doi: 10.1001/archpsyc.1988.01800320037004. [DOI] [PubMed] [Google Scholar]
- 8.Petrides G, Malur C, Braga RJ, et al. Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry. 2015 Jan;172(1):52–58. doi: 10.1176/appi.ajp.2014.13060787. [DOI] [PubMed] [Google Scholar]
- 9.Fontenelle LF, Coutinho ES, Lins-Martins NM, et al. Electroconvulsive therapy for obsessive-compulsive disorder: a systematic review. J Clin Psychiatry. 2015 Jul;76(7):949–957. doi: 10.4088/JCP.14r09129. [DOI] [PubMed] [Google Scholar]
- 10.Pfeiffer PN, Valenstein M, Hoggatt KJ, et al. Electroconvulsive therapy for major depression within the Veterans Health Administration. J Affect Disord. 2011 Apr;130(1–2):21–25. doi: 10.1016/j.jad.2010.09.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Nordanskog P, Hulten M, Landen M, et al. Electroconvulsive Therapy in Sweden 2013: Data From the National Quality Register for ECT. J ECT. 2015 Dec;31(4):263–267. doi: 10.1097/YCT.0000000000000243. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Wang ZM, Zhu H, Pan YL, et al. Electroconvulsive therapy and its association with demographic and clinical characteristics in Chinese psychiatric patients. J ECT. 2015 Jun;31(2):114–118. doi: 10.1097/YCT.0000000000000181. [DOI] [PubMed] [Google Scholar]
- 13.Plakiotis C, George K, O’Connor DW. Has electroconvulsive therapy use remained stable over time? A decade of electroconvulsive therapy service provision in Victoria, Australia. Aust N Z J Psychiatry. 2012 Jun;46(6):522–531. doi: 10.1177/0004867412440190. [DOI] [PubMed] [Google Scholar]
- 14.Scott AI, Fraser T. Decreased usage of electroconvulsive therapy: implications. Br J Psychiatry. 2008 Jun;192(6):476. doi: 10.1192/bjp.192.6.476. [DOI] [PubMed] [Google Scholar]
- 15.Leiknes KA, Jarosh-von Schweder L, Hoie B. Contemporary use and practice of electroconvulsive therapy worldwide. Brain Behav. 2012 May;2(3):283–344. doi: 10.1002/brb3.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi: 10.1016/0021-9681(87)90171-8. [DOI] [PubMed] [Google Scholar]
- 17.Rosner B. Fundamentals of Biostatistics. Boston, MA: Brooks/Cole; 2010. [Google Scholar]